FDA
-
-
-
-
-
-
-
Lucid Capital Markets Downgrades aTyr Pharma (ATYR) to Neutral
-
-
-
-
-
-
-
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECTâ„¢ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

